Similarly, using single-cell data from an EGFR mutant non-small cell lung cancer (NSCLC) cell line treated with the EGFR inhibitor erlotinib [13], we predicted that 40% of cells were likely to exist in a G0 arrest state prior to treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.